C. Payan
Research Subjects
Research Interests
C. Payan has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
F. Lunel
8 shared publicationsA. Ducancelle
4 shared publicationsH. Le Guillou-Guillemette
4 shared publications- A. Pivert
Laboratoire de bactériologie virologie hygiène hospitalière, CHU de Angers, France
3 shared publications I. Fouchard-Hubert
3 shared publicationsJ Loison
3 shared publications
Latest Publications
- 1 June 2010
- Published by Elsevier in Archives de Pédiatrie
- Vol. 17 (6) , 6
CL020 - Diversité génotypique des rotavirus aux urgences pédiatriques en France entre 2006 et 2009
- 1 June 2010
- Published by Elsevier in Archives de Pédiatrie
- Vol. 17 (6) , 6
CL020 - Diversité génotypique des rotavirus aux urgences pédiatriques en France entre 2006 et 2009
- 30 September 2009
- Published by Elsevier in Journal of Clinical Virology
- Vol. 46, S12
OP5-6 Evaluation of human papillomavirus (HPV) by quantification and typing in paired urine and cervical samples of women with abnormal cytology
- 30 September 2009
- Published by Elsevier in Journal of Clinical Virology
- Vol. 46, S12
OP5-6 Evaluation of human papillomavirus (HPV) by quantification and typing in paired urine and cervical samples of women with abnormal cytology
- 31 December 2006
- Published by Elsevier in Journal of Clinical Virology
- Vol. 36, S12-12
Papillomavirus (HPV) DNA load evaluation in urine and cervical samples
- 31 December 2006
- Published by Elsevier in Journal of Clinical Virology
- Vol. 36, S12-12
Papillomavirus (HPV) DNA load evaluation in urine and cervical samples
- 31 December 2006
- Published by Elsevier in Journal of Clinical Virology
- Vol. 36, S51
Diversity of HIV avidity and cellular immune responses under HAART
- 31 December 2006
- Published by Elsevier in Journal of Clinical Virology
- Vol. 36, S51
Diversity of HIV avidity and cellular immune responses under HAART
- 31 December 2006
- Published by Elsevier in Journal of Clinical Virology
- Vol. 36, S39
Lower hepatitis C virus infections in seropositive patients between 1999 and 2003
- 31 December 2006
- Published by Elsevier in Journal of Clinical Virology
- Vol. 36, S39
Lower hepatitis C virus infections in seropositive patients between 1999 and 2003
- 31 December 2006
- Published by Elsevier in Journal of Clinical Virology
- Vol. 36, S134
P.235 Early virological response in HIV/HCV co-infected patients to IFN or Peg-IFN plus ribavirin assessed by HCV RNA measurement
- 31 December 2006
- Published by Elsevier in Journal of Clinical Virology
- Vol. 36, S134
P.235 Early virological response in HIV/HCV co-infected patients to IFN or Peg-IFN plus ribavirin assessed by HCV RNA measurement
- 31 December 2006
- Published by Elsevier in Journal of Clinical Virology
- Vol. 36, S146-146
P.271 Early HCV viral load determination as a predictive parameter of the response to the antiviral therapy in HCV infected patients
- 31 December 2006
- Published by Elsevier in Journal of Clinical Virology
- Vol. 36, S146-146
P.271 Early HCV viral load determination as a predictive parameter of the response to the antiviral therapy in HCV infected patients
- 28 June 2005
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 12 (4) , 405-413
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study
Summary. This cross‐sectional study aimed to investigate, during a short period between 2000 and 2001, in a large population of patients with chronic hepatitis C, the epidemiological characteristics of hepatitis C virus (HCV) genotypes in France. Data from 26 referral centres, corresponding to 1769 patients with chronic hepatitis C were collected consecutively during a 6‐month period. HCV genotyping in the 5′‐non‐coding region (NCR) was performed in each center using the line probe assay (LiPA, in 63% of cases), sequencing (25%) or primer‐specific polymerase chain reaction (PCR) (12%). HCV genotypes 1a, 1b, 2, 3, 4, 5, non‐subtyped 1 and mixed infection were found in 18, 27, 9, 21, 9, 3, 11 and 1% of our population, respectively. HCV genotype distribution was associated with gender, age, source and duration of infection, alanine aminotransferase (ALT) levels, cirrhosis, alcohol consumption, hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection. In multivariate analysis, only the source of infection was the independent factor significantly associated with genotype (P = 0.0001). In conclusion, this study shows a changing pattern of HCV genotypes in France, with i.v. drug abuse as the major risk factor, an increase of genotype 4, and to a lesser extent 1a and 5, and a decrease of genotypes 1b and 2. The modification of the HCV genotype pattern in France in the next 10 years may require new therapeutic strategies, and further survey studies.
- 28 June 2005
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 12 (4) , 405-413
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study
Summary. This cross‐sectional study aimed to investigate, during a short period between 2000 and 2001, in a large population of patients with chronic hepatitis C, the epidemiological characteristics of hepatitis C virus (HCV) genotypes in France. Data from 26 referral centres, corresponding to 1769 patients with chronic hepatitis C were collected consecutively during a 6‐month period. HCV genotyping in the 5′‐non‐coding region (NCR) was performed in each center using the line probe assay (LiPA, in 63% of cases), sequencing (25%) or primer‐specific polymerase chain reaction (PCR) (12%). HCV genotypes 1a, 1b, 2, 3, 4, 5, non‐subtyped 1 and mixed infection were found in 18, 27, 9, 21, 9, 3, 11 and 1% of our population, respectively. HCV genotype distribution was associated with gender, age, source and duration of infection, alanine aminotransferase (ALT) levels, cirrhosis, alcohol consumption, hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection. In multivariate analysis, only the source of infection was the independent factor significantly associated with genotype (P = 0.0001). In conclusion, this study shows a changing pattern of HCV genotypes in France, with i.v. drug abuse as the major risk factor, an increase of genotype 4, and to a lesser extent 1a and 5, and a decrease of genotypes 1b and 2. The modification of the HCV genotype pattern in France in the next 10 years may require new therapeutic strategies, and further survey studies.